# Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis

> **NCT01517282** · PHASE1,PHASE2 · COMPLETED · sponsor: **MorphoSys AG** · enrollment: 32 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** MOR103
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01517282
- **Lead sponsor:** MorphoSys AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2014-01
- **Final completion:** 2014-02
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2014-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01517282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01517282, "Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01517282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*